Observational studyInternational urology and nephrology2026
Impact of androgen deprivation therapy on the cardiovascular functions in men with prostate cancer.
Observational study in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate cancer is prevalent among men, and Androgen Deprivation Therapy (ADT) remains a cornerstone in managing advanced stages of this disease. However, ADT has been associated with cardiovascular side effects, raising concerns, especially in populations with a high baseline risk for cardiovascular diseases. This study aims to investigate the impact of ADT on cardiac function over a short-term follow-up in prostate cancer patients from Southeast Asia. MATERIAL AND
methodThis prospective observational study was conducted from December 2022 to March 2025. Seventy prostate cancer patients who required ADT were recruited and we analysed the outcomes of the whole cohort as well as the comparisons between the Degarelix group, and the Non-Degarelix group. Echocardiographic, ECG and blood investigations were conducted pre-treatment (M1) and at three months post-therapy (M2). Statistical analysis, including paired t-tests and Wilcoxon signed-rank tests, was applied to determine significant changes, with p < 0.05 considered statistically significant.
resultsThe echocardiographic analysis demonstrated a statistically significant reduction in LVEF% (p < 0.001), GLS% (p < 0.001) and a significant elevation of Hs Trop-I (p < 0.001) and NT Pro-BNP (p < 0.001) were noted at M2. Additionally, significant ECG findings included QRS prolongation (p = 0.027) observed in the overall cohort and QTc prolongation (p = 0.006) noted in both the Non-Degarelix group and the overall cohort. The lipid profile analysis revealed elevated total cholesterol, triglycerides and HDL.
conclusionADT appears to have a negative impact on Cardiovascular health. However, patients who received Degarelix seem to have less pronounced effects on cardiovascular parameters compared to the group who received Non-Degarelix treatments.
Indexed as
Identifiers
41315122What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.